OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
August 05, 2022
The OMNI Electric Utility Raceway power and data management system is designed to reduce risk and accelerate cleanroom delivery.
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
August 04, 2022
Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.
Better clinical data are needed, as well as strategies for tackling opioid abuse, tobacco use, and food safety.
Pharmaceutical Technology spoke with Niamh Lynch, Executive Director, Global Head of Quality, Lonza Small Molecules, Basel about best practices for API quality and the impact of the nitrosamine contamination situation.
August 03, 2022
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.
A comprehensive understanding of potential material change can mitigate its impact on patient safety.
Innovations in single-cell analytics have advanced the progression of cell biology research, which has brought new understanding of disease mechanisms.
The nitrosamines contamination in “sartan” drugs emphasized the importance of risk assessment in the manufacture of active pharmaceutical ingredients.
This article reviews sources of excipient variability, including raw materials and processing, both of which may vary from supplier to supplier and from plant to plant for a single manufacturer.